Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 + MEK162 in adults with NRAS-mutant melanoma
NL-OMON44775Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib and binimetinib in cutaneous melanoma (CM) and cutaneous malignancy, sponsored by Pfizer. Primary endpoints: Incidence of dose-limiting toxicities and Overall response rate. Started Jul 2013; status: active, not recruiting.
02
Drugs
ribociclibbinimetinib
03
Conditions
cutaneous melanoma (CM)cutaneous malignancy
Beyond the preview
Go deeper on NL-OMON44775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44775.